Issues affecting the 340B drug pricing program, drug prices, and health care costs
Lobbyists:
HENRY WAXMAN — covered position: US House of Representatives 1975 to 2015
JEREMY SHARP — covered position: LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 [new]
Government entities lobbied:HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
Lobbyists:
HENRY WAXMAN — covered position: US House of Representatives 1975 to 2015
JEREMY SHARP — covered position: LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17
Government entities lobbied:HOUSE OF REPRESENTATIVES; SENATE
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.